Analysts Set Expectations for NTLA FY2027 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities researchers at Zacks Research issued their FY2027 EPS estimates for shares of Intellia Therapeutics in a research note issued to investors on Thursday, March 20th. Zacks Research analyst R. Department forecasts that the company will earn ($4.87) per share for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

Several other research analysts have also recently commented on NTLA. Morgan Stanley cut shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Citigroup increased their price target on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. The Goldman Sachs Group reiterated a “sell” rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. Oppenheimer decreased their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Finally, HC Wainwright started coverage on Intellia Therapeutics in a research report on Wednesday, March 5th. They set a “buy” rating and a $30.00 price target on the stock. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Intellia Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $37.56.

Intellia Therapeutics Stock Up 3.4 %

Shares of NTLA stock opened at $9.31 on Monday. The company has a market cap of $963.74 million, a P/E ratio of -1.71 and a beta of 1.97. The business has a 50 day moving average of $10.07 and a two-hundred day moving average of $14.05. Intellia Therapeutics has a 52 week low of $8.30 and a 52 week high of $28.23.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in Intellia Therapeutics during the fourth quarter valued at approximately $25,000. Sterling Capital Management LLC boosted its holdings in Intellia Therapeutics by 866.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock worth $37,000 after purchasing an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC acquired a new position in Intellia Therapeutics during the fourth quarter worth $40,000. Resona Asset Management Co. Ltd. bought a new position in Intellia Therapeutics during the fourth quarter valued at about $43,000. Finally, Jones Financial Companies Lllp lifted its position in shares of Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after buying an additional 2,280 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold 29,000 shares of company stock valued at $352,551 over the last three months. 3.20% of the stock is owned by corporate insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.